The LADI clinical trial (NCT03172377) aimed to demonstrate non-inferiority and cost-effectiveness of extending the adalimumab dosing interval in patients with Crohn’s disease in stable remission, when compared to standard dosing. We caught up with Reinier van Linschoten (Franciscus Gasthuis & Vlietland; and Erasmus MC, Rotterdam, the Netherlands) to discuss the aims, design, eligibility criteria and findings of the LADI clinical trial.
The abstract entitled ‘CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL’ (Abstract no: OP106) was presented at UEG Week, October 8 – 11, 2022.
- What were the aims, design and eligibility criteria of the LADI clinical trial? (0:22)
- What were the primary and secondary outcome measures, and how well were they achieved in the two treatment groups? (1:54)
- On the basis of these findings, should the dose interval be increased and if so, in which patients? (4:22)
Disclosures: Reinier van Linschoten has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed as a highlight of UEG Week 2022.
Share this Video
Related Videos In Digestive Disorders
UEG Young Talent Group – aims, key achievements and opportunities for early career gastroenterologists: Pilar Acedo
The UEG Young Talent Group (YTG) encourages young gastroenterologists to develop their careers through education, networking and training. We were delighted to catch up with UEG YTG Chair Dr. Pilar Acedo to discuss the training, education and professional opportunities available to young digestive healthcare specialists through UEG, the aims and key achievements of the UEG […]
Highlights from Digestive Disease Week 2023: Gil Y. Melmed
Digestive Disease Week took place between 6-9 May, in this touchIMMUNOLOGY interview, we caught up with our Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) around his personal highlights from this year’s conference including non-pivotal clinical trial data analysing established inflammatory bowel disease (IBD) therapies such as vedolizumab, data around the […]
Comparison study of upadacitinib and tofacitinib as induction treatment in ulcerative colitis: Gil Y. Melmed, DDW 2023
Upadacitinib and tofacitinib are both JAK inhibitors (JAKis) approved by the FDA for the treatment of ulcerative colitis. In this interview with Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) we discuss the aims, design and findings from his study presented at DDW 2023, comparing the efficacy and safety of these […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!